Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Adbry Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Manufacturer
Generic Availability
Mechanism of Action
Adbry Indications
Indications
Moderate to severe atopic dermatitis in patients whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. May be used with or without topical corticosteroids.
Adbry Dosage and Administration
Adult
Give by SC inj into the thigh or abdomen (except for 2 inches around the navel); upper arm may be used if caregiver administers inj. Rotate inj sites. ≥18yrs: Initially 600mg (four 150mg inj), followed by 300mg (two 150mg inj) every other week. After 16 weeks, may consider 300mg every 4 weeks for patients weighing <100kg who achieve clear or almost clear skin. Concomitant topical calcineurin inhibitors: reserve for problem areas only (eg, face, neck, intertriginous, genital areas).
Children
<12yrs: not established. Give by SC inj into the thigh or abdomen (except for 2 inches around the navel); upper arm may be used if caregiver administers inj. Rotate inj sites. 12–17yrs: Initially 300mg (two 150mg inj), followed by 150mg every other week. Concomitant topical calcineurin inhibitors: reserve for problem areas only (eg, face, neck, intertriginous, genital areas).
Administration
Adbry Contraindications
Not Applicable
Adbry Boxed Warnings
Not Applicable
Adbry Warnings/Precautions
Warnings/Precautions
Adbry Pharmacokinetics
Absorption
Absolute bioavailability: ~76%. Time to maximum concentrations: 5 to 8 days.
Distribution
Volume of distribution: ~4.2 L.
Elimination
Adbry Interactions
Interactions
Adbry Adverse Reactions
Adverse Reactions
Adbry Clinical Trials
See Literature
Adbry Note
Not Applicable
Adbry Patient Counseling
See Literature
